Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC).

被引：5

作者：

Argiles, Guillem ^{[1
,2
]}

Jungels, Christiane ^{[3
]}

Garcia-Carbonero, Rocio ^{[4
]}

Garcia, Marc Diez ^{[1
,5
]}

Bendell, Johanna C. ^{[6
]}

Tabernero, Josep ^{[1
,5
]}

Bekradda, Mohamed ^{[7
]}

van Bueren, Jeroen Lammerts ^{[8
]}

Bol, Kees ^{[8
]}

Stalbovskaya, Viktoriya ^{[8
]}

Fatrai, Szabolcs ^{[8
]}

Brinkman, Arjen ^{[8
]}

Wasserman, Ernesto ^{[8
]}

Hollebecque, Antoine ^{[9
]}

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Inst Oncol VHIO, CIBERONC, TTD Grp, Barcelona, Spain

[3] Unversite Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[4] Hosp Univ 12 Octubre, CNIO, UCM, Imas12, Madrid, Spain

[5] Inst Oncol VHIO, Barcelona, Spain

[6] Sarah Cannon, Nashville, TN USA

[7] Oncol Therapeut Dev, Clichy, France

[8] Merus NV, Utrecht, Netherlands

[9] Inst Gustave Roussy, Villejuif, France

来源：

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.62

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2